There are numerous large and small players operating in the global antihypertensive drugs market. Owing to the loss of patents of major branded antihypertensive drugs in the recent years, many players have entered into the market with generic drugs which has led to the significant loss of market share of major players operating in the market.
Some prominent players in the global antihypertensive drugs market are Novartis AG, United Therapeutics Corporation, Daiichi Sankyo Company, Ltd, Sanofi, Bayer AG, Boehringer Ingelheim GmbH, AstraZeneca Plc among others.
Novartis AG accounted for a market share of 6% in 2017. The share of the company is due to its antihypertensive its products Diovan/Co-Diovan and Exforge. The company’s share was affected by the high genericization of its antihypertensive drugs. Novartis AG has strong brand name along with extensive global presence. The company is currently focusing in development of new products to increase its revenue generation. Moreover, the company is also engaged in strategic collaborations and mergers to strengthen its position in the pharmaceutical segment.
United Therapeutics Corporation accounted for a market share of 5% in the year 2017. The company has decent product portfolio for pulmonary arterial hypertension (PAH). United Therapeutics Corporation has strong market penetration in the US market. The company has increased its focus on expanding its business in the international market.
Daiichi Sankyo Company, Ltd held a market share of 5% in 2017. The company is engaged in strategic merger activities which has helped in strengthening its brand image. The company is involved in developing new drugs for treating hypertension which is expected to increase its market revenue in the coming years. For instance, in September 2017, the company announced that the Phase 3 study for Esaxerenone for treatment of essential hypertension in Japan was successful and showed positive outcomes.
The others segment accounted for market share of 70% in 2017 as there are large number of companies operating in this market. These companies are involved in the manufacturing of different classes of antihypertensive drugs such as diuretics, ACE inhibitors, ARBs, calcium channel blockers, beta-adrenergic blockers, renin inhibitors, and vasodilators. Some of these companies are listed below.
Diuretics are manufactured by numerous companies which includes Validus Pharmaceuticals LLC, Teva Pharmaceuticals Industries (Actavis Pharma). Hikma Pharmaceuticals, Amneal Pharmaceuticals LLC, Upsher-Smith Laboratories, LLC, Apotex Corporation, Aa Pharma Inc., Salix Pharmaceuticals, Ipca Laboratories Limited, and Sanis Health among others.
ACE inhibitors are manufactured by companies namely Pharmel Inc., Lek Pharmaceuticals, Sterimax Inc., Sandoz Incorporated, Cipla Limited, Sivem Pharmaceuticals ULC, Valeant Pharmaceuticals Inc., Laboratoire Riva, Auro Pharma Inc., and Camber Pharmaceuticals.
Calcium channel blockers are manufactured by numerous prominent companies such as Ranbaxy Inc., Macleods Pharmaceuticals Limited, Jamp Pharma Corporation, Wockhardt USA LLC., Glenmark Pharmaceuticals Inc., Par Pharmaceutical, Jubilant Cadista Pharmaceuticals Inc., Sun Pharmaceutical Industries Limited, and Mylan Pharmaceuticals.
Beta-Adrenergic blockers are manufactured by companies such as AvKARE, Inc., Watson Pharmaceuticals, Citron Pharma LLC, Unichem Pharmaceuticals (USA), Inc., and Blenheim Pharmacal, Inc.
Michael Porter's five forces model gives a framework that models the global antihypertensive drugs market which is influenced by five forces. The strategic business manager trying to create an edge over competitive firms in the global antihypertensive drugs market and can utilize this model to comprehend better the industry connection in which the firm operates. The components of each of the forces and the degree of impact of each component in the context of the global antihypertensive drugs market industry have been broken down and analyzed.
